Get The App!
Loading the player...
ROS-1 Rearrangements: What are they, and who has them?
Share by Email
Send to social websites
Report this video as inappropriate
You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email.
Select your reason
Violent or Repulsive Content
Hateful or Abusive Content
Harmful Dangerous Acts
Dr. David Ross Camidge, MD, PhD, University of Colorado Denver School of Medicine, discusses issues surrounding ROS-1 Rearrangements, filmed at IASLC 2015.
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
Crizotinib for First Line Treatment of ALK or ROS-1 Rearrangements
What are the Goals of Treating Advanced NSCLC?
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance
ALK Rearrangements: What are they, and who has them?
Zoledronate or Denosumab for Lung Cancer with Bone Metastases
Variability in Pace/Natural History of Progression in Lung Cancer
Copyright 2020 by NSCI Group, Inc.
On The Go
About MedEd On The Go